GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026
GeneDx Holdings Corp. - Class A (WGS)
Company Research
Source: Business Wire
Reported fourth quarter 2025 revenues of $121.0 million with 32% year-over-year growth in exome and genome test revenue (42% excluding a one-time 2024 benefit)Accelerated exome and genome volume growth to 34% year-over-yearReported fourth quarter 2025 adjusted gross margin1 of 71%Reported fourth quarter 2025 adjusted net income1 of $4.4 millionReaffirmed full year 2026 guidance of $540 to $555 million in revenue with 33-35% exome and genome growthGeneDx to host conference call today at 8:30 a.m. ET GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for the fourth quarter and full year of 2025.“The unmet need for early, accurate genomic diagnosis is enormous, and families are waiting far too long for answers. GeneDx is uniquely positioned to deliver for patients, clinicians, and partners — and our results demonstrate that. Our team i
Show less
Read more
Impact Snapshot
Event Time:
WGS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WGS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WGS alerts
High impacting GeneDx Holdings Corp. - Class A news events
Weekly update
A roundup of the hottest topics
WGS
News
- GeneDx (WGS) was upgraded by Zacks Research from "hold" to "strong-buy".MarketBeat
- HALPER SADEH LLC ENCOURAGES GENEDX HOLDINGS CORP. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTSPR Newswire
- GeneDx to Participate in Upcoming Investor ConferencesBusiness Wire
- How The GeneDx Holdings (WGS) Narrative Is Shifting With GenomeDx Prenatal And Valuation Expectations [Yahoo! Finance]Yahoo! Finance
- GeneDx Holdings Corp. (WGS) Surged Following Strong Earnings and Improved Guidance [Yahoo! Finance]Yahoo! Finance
WGS
Earnings
- 2/23/26 - Beat
WGS
Sec Filings
- 2/23/26 - Form S-8
- 2/23/26 - Form 10-K
- 2/23/26 - Form 8-K
- WGS's page on the SEC website